Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His27 and Arg27 carriers

Clinical Cancer Research

Volumn 7, Issue 11, 2001, Pages 3416-3422

  Whetstine, Johnathan R ^a   Gifford, Andrew J ^c   Witt, Teah ^a   Liu, Xiang Y ^a   Flatley, Robin M ^a   Norris, Murray ^c   Haber, Michelle ^c   Taub, Jeffrey W ^a,b   Ravindranath, Y ^a,b   Matherly, Larry H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; ARGININE; EDATREXATE; FOLIC ACID; FOLINIC ACID; HISTIDINE; LOMETREXOL; METHOTREXATE; RALTITREXED; TETRAHYDROFOLIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; BLAST CELL; CONTROLLED STUDY; DNA SEQUENCE; EXON; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE INSERTION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; B-LYMPHOCYTES; BASE SEQUENCE; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHILD; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; DNA, NEOPLASM; GENE FREQUENCY; HUMANS; K562 CELLS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MUTAGENESIS, INSERTIONAL; PLASMIDS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, NEOPLASM; STEM CELLS; TRANSFECTION;

EID: 0035187308     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Historical perspective on key advances in the biochemistry and physiology of folates
2. The cellular pharmacology of methotrexate
3. Carrier-mediated membrane transport of folates in mammalian cells
4. Receptor- and carrier-mediated transport systems for folates and antifolates: Exploitation for folate-based chemotherapy and immunotherapy
5. Folic acid and the prevention of birth defects
6. Folate: Effects on carcinogenesis and the potential for cancer chemoprevention
7. Homocysteine and cardiovascular disease
8. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport-deficient cells
9. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake
10. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells
11. Molecular cloning of the human placental folate transporter
12. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake
13. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells
14. Structural analysis of the human RFC-1 gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5′ end heterogeneity
15. Structure and organization of the human reduced folate carrier gene
16. Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental cells
17. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake
18. Molecular mechanism of antifolate transport deficiency in a methotrexate resistant MOLT-3 human leukemia cell line
19. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance
20. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier
21. Initial sequencing and analysis of the human genome
22. The sequence of the human genome
23. Pharmacogenomics: Unlocking the human genome for better drug therapy
24. Dissecting human disease in the postgenomic era
25. A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia
26. Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro
27. Edatrexate, an antifolate with antitumor activity: A review
28. GW1843: A potent, noncompetitive thymidylate synthase inhibitor - Preclinical and preliminary clinical studies
29. Raltitrexed, a polyglutamatable antifolate thymidylate synthase inhibitor: Design and preclinical activity
30. Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors Lometrexol and LY309887
31. Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity
32. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children
33. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy
34. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction
35. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport
36. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
37. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes
38. Protein measurement with the Folin phenol reagent
39. Mutations in the reduced folate carrier gene (RFC) in childhood acute lymphoblastic leukemia (ALL)
40. A mutated reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function
41. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate
42. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate
43. Pharmacogenomics: Translating functional genomics into rational therapeutics